Lexicon Pharmaceuticals, Inc. (LXRX) |
|
2.8198 -0.21 (-6.94%)
|
06-09 15:01 |
|
Open: |
3.02 |
Pre. Close: |
3.03 |
|
High:
|
3.0301 |
Low:
|
2.79 |
|
Volume:
|
2,221,359 |
Market Cap:
|
690(M) |
|
|
|
Technical analysis |
as of: 2023-06-09 2:46:10 PM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 3.83 One year: 4.42 |
| Support: |
Support1: 2.46 Support2: 2.04 |
| Resistance: |
Resistance1: 3.28 Resistance2: 3.78 |
| Pivot: |
2.93 |
| Moving Average: |
MA(5): 2.79  MA(20): 2.93
MA(100): 2.51 MA(250): 2.43 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 45.3 %D(3): 36.3 |
| RSI: |
RSI(14): 49.4 |
| 52-week: |
High: 3.78 Low: 1.3 |
| Average Vol(K): |
3-Month: 1,780 (K) 10-Days: 6,375 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ LXRX ] has closed above bottom band by 37.8%. Bollinger Bands are 48.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.12 - 3.13 |
3.13 - 3.14 |
|
Low:
|
2.8 - 2.81 |
2.81 - 2.82 |
|
Close:
|
3.01 - 3.03 |
3.03 - 3.05 |
|
Company Description |
|
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas. |
Headline News |
Wed, 07 Jun 2023
Is Lexicon Pharmaceuticals Inc (LXRX) a Winner in the Healthcare Sector? - InvestorsObserver
Tue, 06 Jun 2023
Lexicon Pharmaceuticals to Participate in the Jefferies 2023 Global Healthcare Conference - Yahoo Finance
Tue, 06 Jun 2023
Lexicon stock gains after closing equity raise (NASDAQ:LXRX) - Seeking Alpha
Thu, 01 Jun 2023
Healthcare Stocks Moving Thursday: REUN, NNVC, VEEV, CGTX, HOOK, LXRX, KPRX, IVVD - InvestorsObserver
Wed, 31 May 2023
Lexicon Pharmaceuticals Inc (LXRX) has gained 7.84% in a Week, Should You Buy? - InvestorsObserver
Tue, 30 May 2023
HP, Lexicon Pharmaceuticals And 3 Stocks To Watch Heading Into Tuesday - HP (NYSE:HPQ), Box (NYSE:BOX) - Benzinga
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
190 (M) |
|
% Held by Insiders
|
8.129e+007 (%) |
|
% Held by Institutions
|
1.1 (%) |
|
Shares Short
|
4,200 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.0809e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-86 |
|
Return on Assets (ttm)
|
128.5 |
|
Return on Equity (ttm)
|
-45.4 |
|
Qtrly Rev. Growth
|
126000 |
|
Gross Profit (p.s.)
|
-26.4 |
|
Sales Per Share
|
-91.85 |
|
EBITDA (p.s.)
|
-3.9609e+007 |
|
Qtrly Earnings Growth
|
-0.6 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-97 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.04 |
|
Price to Cash Flow
|
8.19 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
6.45e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
